Drug Profile
Anti-CD20 monoclonal antibody BCA B20
Alternative Names: Anti-CD20 monoclonal antibody; BCA-B20Latest Information Update: 25 Nov 2021
Price :
$50
*
At a glance
- Originator Unknown
- Developer Nonindustrial source
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD20 antigen inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 23 Oct 1997 No-Development-Reported for Cancer in Netherlands (Unknown route)
- 04 Apr 1995 Preclinical development for Cancer in Netherlands (Unknown route)